BCIC
LightNews LightNews
bcic.bsky.social
BCIC
@bcic.bsky.social
2 followers 1 following 15 posts
Boston Capital Investment Club
Posts Replies Media Videos
bcic.bsky.social
A trusted China clinical development partner joins the Boston Capital Investment Club ecosystem! 🎉

We’re excited to introduce PanaCRO, a full-service clinical CRO and long-term clinical development partner in China.

#Biotech #Startups #CRO #VentureCapital #Biomedical #PitchCompetition #BCIC
🔬At a glance 800+ clinical professionals 200+ international clients Global presence across China, the U.S., Australia 🔬Core expertise Phase I–III clinical trial execution IITs as a complementary and flexible development strategy Full clinical services: Regulatory, Medical, Clinical Ops, DM, Statistics, PV Strong experience in oncology, autoimmune, CNS, ophthalmology, metabolic & infectious diseases, including cell & gene therapies (ex vivo & in vivo CAR-T) 🌐Why China. Why PanaCRO. China offers unique advantages in patient access, enrollment speed, and site maturity—and PanaCRO brings the local execution strength and global-standard rigor needed to run complex trials with confidence. With trusted partners like PanaCRO joining the BCIC ecosystem, we continue to expand not only clinical development capabilities for innovators but also the capital, visibility, and strategic resources that help early-stage biotech companies scale globally. 🎉If you’re building the next breakthrough therapy, this is exactly the type of ecosystem designed to support you. The 2026 Biomedical Pitch Competition has been open for registration. Don’t miss your chance to gain the visibility and support needed to scale your breakthrough. Register now:(https://lnkd.in/ePTt9247) Also our upcoming webinar: Unlocking Pre-IPO Investing: Democratizing Access to High-Growth Private Equity Date: February 12, 2026 (Thursday) Time: 7:00 PM – 8:15 PM EST Format: Virtual Only (Zoom Webinar) Register Here: (https://lnkd.in/eiemMvQt) Don’t miss this opportunity to explore the next paradigm of private equity investment!
February 7, 2026 at 3:33 AM
bcic.bsky.social
Accelerating Targeted Alpha Therapies: AdvanCell & 48Hour Discovery Join Forces 🔬

Big news in the radiopharmaceutical space! #AdvanCell has officially entered a Collaboration and Exclusive Licensing Agreement with #48Hour Discovery to develop a novel peptide-based Lead-212 (212Pb) radiotherapeutic.
This partnership targets gastrointestinal cancers with significant unmet medical needs, combining two powerhouse platforms: #48Hour Discovery’s rapid peptide discovery engine. #AdvanCell’s scalable 212Pb platform and clinical expertise. By integrating secure isotope supply with precision-engineered peptides, this program is set for a rapid path to the clinic in 2027. Following the recent success of AdvanCell’s lead program (ADVC001), this expansion reinforces the potential of Alpha Therapy to transform outcomes for cancer patients globally. #BCIC #Bostoncapitalinvestmentclub #Radiopharmaceuticals #AlphaTherapy #Oncology
February 3, 2026 at 11:48 PM
bcic.bsky.social
RNAi deal worth watching from an investment lens
SanegeneBio announced a global licensing agreement with Genentech (罗氏公司 Group) for an RNAi therapeutic, featuring $200M upfront, up to $1.5B in milestones, plus tiered royalties.
#BiotechInvesting #RNAi #LicensingDeals #PharmaBD #Roche #Genentech
Deal takeaways - Strong platform validation for Shengyin’s RNAi chemistry and delivery technologies - Meaningful non-dilutive capital with retained upside via milestones and royalties - Genentech assumes late-stage development and commercialization risk, a classic risk-sharing structure - Signals continued Big Pharma appetite for RNAi assets, especially platform-driven programs From an investment perspective, this deal highlights how differentiated RNA platforms can command premium economics even at early clinical stages—and how large pharma is selectively re-entering RNAi with improved delivery solutions.
February 3, 2026 at 11:46 PM
bcic.bsky.social
In recent years, companies like AbbVie (Vuity), LENZ Therapeutics (Vizz), and Orasis Pharmaceuticals (Qlosi) have launched eye drops that temporarily improve near vision by shrinking the pupil. These drops kick in within ~15–30 minutes, offering a glasses-free option for part of the day.
#BCIC
By some estimates, presbyopia affects 128M people in the U.S. and nearly 2B worldwide. It’s not a disease, but an inevitable part of aging: as we get older, the eye’s lens stiffens, making it harder to focus on close-up objects. For decades, the fix has been simple: reading glasses, contacts, or bifocals. That’s starting to change. In recent years, companies like AbbVie (Vuity), LENZ Therapeutics (Vizz), and Orasis Pharmaceuticals (Qlosi) have launched eye drops that temporarily improve near vision by shrinking the pupil. These drops kick in within ~15–30 minutes and last a few hours, offering a glasses-free option for part of the day. Now, Tenpoint Therapeutics, Ltd. newly approved Yuvezzi may raise the bar. Yuvezzi is the first dual-agent presbyopia drop, combining carbachol and brimonidine tartrate. Together, they constrict the pupil and help prevent it from dilating again, extending the duration of effect. One component also reduces eye redness—an issue seen with earlier drops. Yuvezzi starts working in about 30 minutes and can last up to 10 hours, potentially covering an entire workday. FDA clearance was supported by two Phase 3 trials, showing stronger efficacy than the individual components alone, with relatively low redness rates (~3%). Yuvezzi’s path to market is also notable. Tenpoint Therapeutics, Ltd. emerged in 2023 focused on cell-based vision restoration, raised $70M in Series A, then merged with Visus Therapeutics in 2024, bringing Yuvezzi to the front of its pipeline. Its approval now aligns with a new Series B raise, setting the stage for a commercial launch. For a massive, aging population, presbyopia drops are moving from novelty to mainstream and Yuvezzi could mark a meaningful next step in that evolution.
February 2, 2026 at 8:36 AM
bcic.bsky.social
Big week for Europe’s drug regulators!

The European Medicines Agency’s CHMP just released a new round of recommendations, and they highlight both momentum and caution across pharma.

#BCIC #Oncology #MASH #RareDisease #EU
诺和诺德 scored a major win. Semaglutide has been recommended for conditional approval in Europe to treat non-cirrhotic metabolic dysfunction-associated steatohepatitis MASH (a severe liver disease). Interestingly, it won’t be branded as Wegovy — instead, it’ll launch under a new name: Kayshild. This mirrors the FDA’s recent conditional approval and reinforces how GLP-1s are expanding beyond diabetes and obesity into harder-to-treat metabolic diseases. Rare disease and oncology saw meaningful progress. 优时比’s Kygevvi received a positive opinion under “exceptional circumstances,” potentially becoming the first treatment for TK2 deficiency. Incyte’s Zynzy could become Europe’s first immunotherapy for anal squamous cell carcinoma — a new standard of care if approved. Overall, this CHMP cycle shows how regulators are balancing innovation, unmet need, and data integrity approving boldly where evidence supports it, and slowing down when questions remain. All decisions now head to the European Commission for final approval.
January 31, 2026 at 8:27 PM
bcic.bsky.social
礼来 expands Immunology Footprint with Strategic Repertoire Partnership

礼来 has entered a major collaboration with Repertoire Immune Medicines, committing up to $1.93 B to co-develop novel therapies targeting autoimmune diseases.

#BCIC #Biotech #Immunology #Pharma #Innovation #Lilly #Repertoire
The agreement includes an $85 M upfront investment and up to $1.84 B in milestone and commercial payments, with tiered royalties on potential future sales. This partnership gives 礼来 access to Repertoire Immune Medicines proprietary DECODE platform, which maps T-cell interactions to unlock precision immune-modulating treatments aimed at restoring immune balance without broad suppression. Initially, Repertoire will lead early discovery, with Lilly taking over clinical development, regulatory strategy, and commercialization. Following recent immunology deals, this collaboration underscores Lilly’s commitment to diversifying beyond its established diabetes and obesity portfolio and to advancing innovative solutions for patients living with autoimmune conditions.
January 31, 2026 at 8:25 PM
bcic.bsky.social
This week’s deal flow sends a clean signal: capital is not retreating from innovation—it is becoming more selective about where technical risk is taken and how it is transferred.
#BCIC #BiotechInvesting #AntibodyTherapeutics
#TCellEngagers #BispecificAntibodies #ADC
#GeneTherapy #RareDisease
In antibody therapeutics, large pharma continues to pay for platforms that explicitly address therapeutic index. The 百时美施贵宝-Janux Therapeutics collaboration around a tumor-activated T cell engager reinforces that conditional activation remains one of the most credible strategies for expanding the use of TCEs in solid tumors. When platform design is anchored in safety control rather than brute-force potency, preclinical assets can still command meaningful economics. A similar logic appears in autoimmune disease. 勃林格殷格翰’s billion-euro-scale bet on a TL1A×IL-23 bispecific reflects confidence that pathway convergence, rather than incremental single-target optimization, may be required to reset efficacy ceilings in chronic inflammatory diseases. Importantly, these deals continue to offload late-stage clinical and commercial execution to scaled operators, allowing early innovators to monetize platform risk earlier. What stands out this week, however, is the contrast provided by gene medicine. 礼来’s >$1.1B collaboration with Seamless Therapeutics around a programmable recombinease platform for hereditary hearing loss highlights that gene therapy capital is re-entering the market—but in a more disciplined form. The emphasis is no longer on editing novelty alone, but on programmability, precision, and clinical tractability. In many ways, this mirrors where antibody investing was a decade ago. Two cross-modality patterns are becoming clearer: - Platform optionality is favored over single-asset heroics - Safety, controllability, and manufacturability increasingly drive valuation - Big pharma prefers structured deals that preserve downside while securing long-term upside The antibody and gene therapy worlds are converging—not in modality, but in investment logic. The next winners will be platforms that convert uncertainty into engineering problems.
January 29, 2026 at 4:18 PM
bcic.bsky.social
Another industry leader is on board!

We are thrilled to announce that Porton Pharma Solutions Ltd. (SZSE: 300363), a publicly listed company, has joined us as a key supporter for our 2026 Biomedical Pitch Competition.

#Biotech #Startups #CDMO #VentureCapital #Biomedical #PitchCompetition #BCIC
Founded in 2005, Porton Pharma Solutions is a world-class CDMO, empowering global clients across the drug development spectrum—from Small Molecules and Biologics to Advanced Therapy Medicinal Products (ADCs, PDCs, RDCs). Their expertise from pre-clinical to commercialization is an invaluable asset to our ecosystem. 👏 Entrepreneurs: This is your chance to pitch in front of industry giants and top-tier VCs. Don't miss this marketplace opportunity! 🔗 Apply/Register here: https://lnkd.in/ePTt9247
January 29, 2026 at 4:14 PM
bcic.bsky.social
Why China’s early-stage drugmaking edge is the most compelling “de-risked” opportunity in 2026.

The latest Pitchbook analyst note on the Chinese biopharma landscape is a wake-up call for global asset allocators.

#BCIC #VentureCapital #Pitchbook #ChinaBiotech #AssetAllocation #CGT #ADC
The narrative has officially shifted: China is no longer a "fast-follower"—it has become the global engine for First-in-Human (FIH) innovation.As an investor, three data points from this report stand out as strategic signals for the year ahead: 1. The Efficiency Moat: Since 2021, China has registered nearly twice as many FIH trials for next-gen antibodies (ADCs, bispecifics) as the U.S. and Europe combined. In an era where "speed to data" is everything, China’s clinical infrastructure is delivering results at a fraction of the cost. 2. From "Me-Too" to "High-Complexity": Modality mix is evolving rapidly. In 2025, cell and gene therapies (CGT) and nucleic acid assets accounted for 50% of deal volume in China. We are seeing a massive shift toward high-complexity assets that global MNCs are eager to integrate into their pipelines. 3. The Arbitrage Opportunity: Western pharmas are essentially "acquiring de-risked innovation hubs" via licensing rather than full M&A. With U.S. early-stage assets facing funding constraints, the cross-border licensing of underfunded but clinically superior Chinese assets is the most capital-efficient way to bridge the "patent cliff." My Take: The "China Edge" is likely to persist for years. The massive spike in innovative drug submissions—from 688 in 2019 to nearly 2,300 in 2023—is just now reaching the peak of its value realization. For LPs and GPs, the question isn't whether to have exposure to China-originated assets, but how to structure the partnerships to navigate the geopolitical noise while capturing the scientific alpha. Source: [https://lnkd.in/ezEfyWRm](https://lnkd.in/ezEfyWRm)
January 28, 2026 at 8:24 AM
bcic.bsky.social
Why China’s early-stage drugmaking edge is the most compelling “de-risked” opportunity in 2026.

Source: lnkd.in/ezEfyWRm
#BCIC #Bostoncapitalinvestmentclub #BiotechInvesting #VentureCapital #DrugDiscovery #AssetAllocation #CGT #ADC

Images generated with insights from Pitchbook 2026 Report.
January 27, 2026 at 4:05 PM
bcic.bsky.social
Unlocking Pre-IPO Investing: Democratizing Access to High-Growth Private Equity

Join the Boston Capital Investment Club (BCIC) for an exclusive virtual seminar featuring Jarsy Inc, a compliance-first platform dedicated to increasing transparency and accessibility in the Pre-IPO market.
#PreIPO#BCIC
The world of high-growth private equity has long been reserved for a select few. Jarsy Inc is changing that. 📅 Date: February 12, 2026 (Thursday) ⏰ Time: 7:00 PM – 8:15 PM EST 📍 Format: Virtual Only (Zoom Webinar) Featured Speakers: Howard Feng, CFA (Event Chair) – Vice President of BCIC Tony Wang (Moderator) – Partner of Crestwave Capital Qin Han (Panelist) – Founder and CEO of Jarsy Chunyang Shen (Panelist) – Co-founder and CTO of Jarsy Calvin Du (Panelist) – Investment Director at Avenir Group Why Attend? -Gain insights into the technological restructuring of financial infrastructure. -Understand the legal and risk frameworks of modern Pre-IPO platforms. -Explore the application of blockchain and AI in private asset scenarios. 🔗 Register Here: https://lnkd.in/eiemMvQt Don’t miss this opportunity to explore the next paradigm of private equity investment!
January 27, 2026 at 3:36 PM
bcic.bsky.social
百时美施贵宝 just struck another notable oncology deal, this time partnering with Janux Therapeutics to advance a next-generation T cell–based therapy designed to be active only in the tumor microenvironment.
#BCIC #Biotech #Tcells
Under the agreement, 百时美施贵宝 will pay $50M upfront and near-term, with up to ~$800M in development, regulatory, and commercial milestones, plus tiered royalties. The collaboration centers on Janux Therapeutics tumor-activated T cell engager platform, which aims to address one of the biggest limitations of classic T cell engagers: systemic toxicity. Janux's approach uses a masking strategy that keeps the CD3/CD28-binding portion of the molecule inactive in circulation. The mask is cleaved by tumor-associated proteases, activating the therapy only near the tumor and potentially reducing risks like cytokine release syndrome. If it works as intended, this could meaningfully widen the therapeutic window for T cell engagers in solid tumors. The target antigen hasn't been disclosed, other than being expressed across multiple solid tumor types. Janux Therapeutics will handle preclinical work and IND filing, with BMS taking over clinical development after Phase I. Zooming out, this deal fits neatly into 百时美施贵宝's broader strategy. Over the past year, the company has doubled down on oncology and immune-based platforms, from its $1B+ collaboration with Harbour BioMed to access advanced antibody discovery models, to its $1.5B acquisition of Orbital Therapeutics to expand into RNA-enabled cell therapies. While many large pharmas have pulled back from cell therapy, 百时美施贵宝 appears to be leaning in selectively and with an eye toward differentiated technology. This partnership underscores where the field is heading: not just more immune activation, but smarter, more localized immune engagement. If tumor-activated approaches can deliver efficacy without the usual toxicity tradeoffs, they could unlock a much broader role for T cell engagers in solid tumors. Curious to see how this platform performs once it reaches the clinic.
January 26, 2026 at 2:57 AM
bcic.bsky.social
CORXEL Pharmaceuticals announced a $287 million Series D1 financing to advance its oral GLP-1 candidate, CX11, and move several programs further down the clinic.
#BCIC #GLP-1 #Biotech
CORXEL Pharmaceuticals announced a $287 million Series D1 financing to advance its oral GLP-1 candidate, CX11, and move several programs further down the clinic. The proceeds will primarily support completion of Phase II studies of CX11 in the U.S. for overweight and obesity, alongside mid-stage trials in type 2 diabetes. CORXEL Pharmaceuticals also plans to use the capital to prepare for Phase III development. CX11, a once-daily oral GLP-1 receptor agonist, is already in Phase III testing in China under partner Vincentage, and the company says it aims to match the efficacy seen with injectable GLP-1 therapies. Beyond CX11, the funding will help advance other pipeline assets, including JX10 for acute ischemic stroke and JX09, an aldosterone synthase inhibitor being developed for hypertension. The raise comes amid intensifying competition in the oral obesity space. 诺和诺德 recently launched an oral version of Wegovy following FDA approval, while 礼来 is awaiting a regulatory decision on its oral GLP-1 candidate, orforglipron. Corxel’s financing also fits into a broader wave of large biotech fundraises kicking off 2026, signaling renewed investor appetite for late-stage clinical assets. It will be interesting to see how CX11 differentiates as more oral GLP-1 programs move closer to the market.
January 24, 2026 at 3:06 PM
bcic.bsky.social
Three Investment Lessons for 2026 📈

A new year, a new approach to investing. Are you ready for 2026?

#Investing #Finance #AI #MarketTrends #2026#AssetTokenization #Stablecoins #MegaForces
2025 was volatile but instructive. Key takeaways: 1️⃣ Immutable laws constrain extremes – supply chains and fundamentals can’t be rewired overnight. 2️⃣ Mega forces trump the macro – AI and transformative trends drive markets more than traditional macro signals. 3️⃣ Financial systems are evolving fast – stablecoins and asset tokenization are reshaping investment landscapes.
January 22, 2026 at 11:26 AM
bcic.bsky.social
🌺Invitation for 2026 Biomedical Pitch Competition

💊You are invited to the 2026 Biomedical Pitch Competition, connecting biomedical start-ups with investors and other business accelerator resources.
💊Please submit your applications by Feb 28th, 2026. All biomedical startups from concept to pre-IPO are welcome to participate. ⭐Benefits of Firms Participating in Pitch Competition –$300+ mil raised from participant firms in the last four years –Potential direct equity investment from 200+ Angel/VC funds/MNCs -Many top-tier VCs & MNCs serve as final judges –Fundraising, License Out or NewCo opportunities for your technology –Partnership opportunities from venture capitalists, serial entrepreneurs, corporate executives, and attorneys –Media exposure through partners’ networks. (20k+ views) 🎉A Track Record of Impact 2025 Pitch Competition Highlights - 益杰立科 raised $60 million successfully - Groovy Medicine raised funding 2024 Pitch Competition Highlights - Rapafusyn Pharmaceuticals raised $44 million successfully in USA - 巧捷力医疗机器人 secured $10 million successfully from a Singapore family office - 寻百会 secured funding of over $30 million successfully - Affinity Biopharmaceutical secured funding of $55 million - ImmVira filed for IPO 2023 Pitch Competition Highlights - Myrobalan Therapeutics raised $24 million successfully in the US within 5 months after participating in the pitch competition. - Two startups raised $2mil and $2mil separately. - At least one startup landed in Asia - 2022 Pitch Competition Highlights - Amytrx Therapeutics, Inc. has raised $18 million - ARIZ Precision Medicine has raised $3 million - Harvard Apparatus Regenerative Technology (now Biostage, Inc.) has raised $5 million - At least two startups landed in Asia 💡 Timeline: The deadline for registration: Feb 28th, 2026 Preliminary Pitches: March, 2026 Semi Final Pitches: March, 2026 Final Contest: May, 2026 Please register by scanning the QR Code or using the link below Option 1 (preferred): Google Form https://lnkd.in/erHD3v9q Option 2: JinshuJu form https://lnkd.in/e77SNPrV
January 21, 2026 at 2:47 AM